Korean vs European Aesthetic Injectables: A Practitioner's Comparison Guide
The UK aesthetic injectable market has undergone a significant shift over the past decade. Korean-manufactured aesthetic products — botulinum toxins, hyaluronic acid fillers and skin boosters, PDRN polynucleotides, lipolytic agents, and now exosomes — have moved from being unfamiliar imports to becoming the preferred clinical tools of a growing proportion of UK aesthetic practitioners.
Korean Exosome Products: A Practitioner's Guide to Selection and Use
The aesthetic exosome market is growing rapidly and unevenly. Alongside genuinely well-characterised, rigorously manufactured Korean products with transparent documentation, the market contains preparations making compelling regenerative claims while providing minimal evidence of their actual content, source, or regulatory classification. For practitioners, the ability to evaluate exosome products on scientific and regulatory grounds is essential.
Korean PDRN Products: A Practitioner's Guide to Selection and Use
South Korea is the world's leading producer of pharmaceutical-grade PDRN injectables. The Korean PDRN industry has been developing, manufacturing, and exporting these products for over two decades — a timeline that gives Korean manufacturers an accumulated clinical knowledge base and manufacturing expertise that no other country's PDRN industry can currently match. For UK and EU practitioners, this means the best available PDRN products are, almost without exception, Korean in origin.
